Arteriocyte, a clinical stage Biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts, is developing proprietary stem cell and tissue engineering based therapies. Arteriocyte’s goal is to develop commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage) for disease where surgical interventions are inadequate.

In 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems, in order to develop and acquire novel medical devices and point of care surgical solutions. Arteriocyte is developing new treatment strategies that couple its novel cellular therapies with the innovative delivery platforms commercially available through Arteriocyte Medical Systems.